Technology evaluation: TransMID, KS Biomedix/Nycomed/Sosei/PharmaEngine.

Article Details

Citation
Copy to clipboard

Rainov NG, Soling A

Technology evaluation: TransMID, KS Biomedix/Nycomed/Sosei/PharmaEngine.

Curr Opin Mol Ther. 2005 Oct;7(5):483-92.

PubMed ID
16248284 [ View in PubMed
]
Abstract

KS Biomedix (formerly Avicenna Medica; now a subsidiary of the Xenova group) and Nycomed, together with Japanese licensee Sosei and Chinese licensee PharmaEngine, are developing TransMID, a transferrin-mediated diphtheria toxin delivery system for the potential treatment of adult, recurrent, inoperable, high-grade glioma (as TransMID-107R). It is also under investigation for other forms of brain cancer, including early brain cancer (as TransMID-107N), metastatic brain cancer (as TransMID-107M) and pediatric brain cancer (as TransMID-107P). TransMID is currently undergoing phase III clinical trials.

DrugBank Data that Cites this Article

Drugs